Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants

Baskent University

Status and phase: Completed; Phase 4

Conditions: Brain Cancer

Treatments: Drug: Sugammadex

Study type: Interventional

Funder types: Other

Identifiers

NCT02708056

KA 16-67

Details and patient eligibility

About

The objective of this study is to evaluate the efficacy and safety of sugammadex in reversing profound neuromuscular block induced by rocuronium in infant patients

Enrollment: 26 patients

Sex: All

Ages: 1 to 12 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients between the ages of 1-12 month,
• ASA physical status 1-3 who underwent elective brain cancer surgery during general anesthesia were included in the study

Exclusion criteria

• younger than 1month or older than 12 months.
• hepatic or renal failure
• A history of allergy to study medication

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

26 participants in 1 patient group

Sugammadex, Bridion

Other group

Description:

Drug were given intravenously by a anesthesiologist at the end of surgery

Treatment:

Drug: Sugammadex